Subtype
Adult-Type Diffuse Glioma
CI-CAN-00009389Explore in graph →
510 active trials2 approved drugs70 evidence items
- OncoTree
- ADIFG
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009389Explore in graph →
Clinical trials
1,869 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (295)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01268566 | A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 62 | MedImmune LLCINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01929720 |
| Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors(FOCUS) |
| completed |
| N/A |
| 33 |
| Ohio State University Comprehensive Cancer CenterOTHER |
| 1 |
| Apr 5, 2017 |
| clinicaltrials |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 30 | Center for Neurosciences, TucsonOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00792012 | A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 37 | University of Colorado, DenverOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | completed | Phase 2 | 124 | Precision Life Sciences GroupINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00459381 | Pazopanib in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01738646 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | completed | Phase 2 | 48 | Duke UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01836536 | Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients(AVA-CELL) | completed | N/A | 30 | Center Eugene MarquisOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01250470 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT01238237 | Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | completed | Phase 1 | 15 | Northwell HealthOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00813943 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status(CORE) | completed | Phase 2 | 265 | EMD SeronoINDUSTRY | 2 | Jan 30, 2017 | clinicaltrials |
| NCT00085540 | FR901228 in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT00777153 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma(REGAL) | completed | Phase 3 | 423 | AstraZenecaINDUSTRY | 10 | Dec 28, 2016 | clinicaltrials |
| NCT00705198 | Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) | completed | — | 1,804 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 15, 2016 | clinicaltrials |
| NCT01308684 | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma | completed | Phase 1 | 22 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01547546 | A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma | completed | Phase 1 | 29 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01443676 | Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma(ARTE) | completed | Phase 2 | 75 | University of ZurichOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT01999270 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT02104882 | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study | completed | Phase 1 / Phase 2 | 12 | Universitätsmedizin MannheimOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00088400 | Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors | completed | Phase 3 | 30 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 22, 2016 | clinicaltrials |
| NCT02899663 | MRI Detection of Microbleeds in Glioma Patients(SWIGLI) | completed | — | 58 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 0 | Sep 14, 2016 | clinicaltrials |
| NCT02898012 | Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status(ATAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT00544817 | Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme | completed | Phase 2 | 47 | SCRI Development Innovations, LLCOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00302159 | Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2016 | clinicaltrials |
| NCT01331291 | Bosutinib in Adult Patients With Recurrent Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00864864 | Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma | completed | Early Phase 1 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2016 | clinicaltrials |
| NCT01588769 | A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients(ALECSAT-GBM) | completed | Phase 1 | 23 | CytoVac A/SINDUSTRY | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01833273 | Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA(DESSTINI_A) | completed | Phase 1 | 13 | Stony Brook UniversityOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01144247 | Cellular Immunotherapy Study for Brain Cancer(alloCTL) | completed | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT00267592 | Safety and Efficacy of Talampanel in Glioblastoma Multiforme | completed | Phase 2 | 72 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 19, 2016 | clinicaltrials |
| NCT01213407 | Dendritic Cell Cancer Vaccine for High-grade Glioma(GBM-Vax) | completed | Phase 2 | 87 | Activartis BiotechINDUSTRY | 1 | May 19, 2016 | clinicaltrials |
| NCT00445588 | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01435395 | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | completed | Phase 1 | 12 | Emory UniversityOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01475006 | AMG 595 First-in-Human in Recurrent Gliomas | completed | Phase 1 | 32 | AmgenINDUSTRY | 2 | Apr 15, 2016 | clinicaltrials |
| NCT00995007 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | completed | Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2016 | clinicaltrials |
| NCT01474239 | A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Mar 15, 2016 | clinicaltrials |
| NCT00326664 | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2016 | clinicaltrials |
| NCT00499473 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00085254 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01364064 | Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 3 | 1,153 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT00250211 | Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | completed | Phase 1 / Phase 2 | 26 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01663012 | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | completed | Phase 2 | 20 | Lawrence RechtOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00301418 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | completed | Phase 1 / Phase 2 | 11 | Northwell HealthOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00789828 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)(EXIST-1) | completed | Phase 3 | 117 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 3, 2016 | clinicaltrials |
| NCT01345370 | Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients(ECOM) | completed | — | 300 | Center Eugene MarquisOTHER | 1 | Jan 29, 2016 | clinicaltrials |
| NCT01113398 | AMG 102 and Avastin for Recurrent Malignant Glioma | completed | Phase 2 | 36 | Katy PetersOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00874861 | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas | completed | Early Phase 1 | 10 | Ian F. Pollack, M.D.OTHER | 1 | Dec 8, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2017source: clinicaltrials